Current approaches for the management of Parkinson’s disease in Chinese hospitals: a cross-sectional survey

Gang Wang†, Hai-Lun Cui†, Jun Liu, Qin Xiao, Ying Wang, Jian-Fang Ma, Hai-Yan Zhou, Jing Pan, Yu-Yan Tan, Sheng-Di Chen* and on behalf of the Chinese Movement Disorders Society

Abstract

Background: Chinese guidelines for management of Parkinson’s disease (PD) have been issued and updated regularly since 2006. We undertook a cross-sectional survey to evaluate the impact of the latest edition (2014) on current approaches to the management of PD based on previous pilot works.

Methods: Seven hundred and seventeen participants, divided into 3 groups (GPs, Neurologists, and Specialists), recruited from 138 randomly chosen hospitals from 30 cities across China, participated by completing the questionnaire describing their current approaches before and after the guidelines were issued.

Results: Considerable discrepancies in management were apparent across the three categories, with different selection of first-choice medication for PD patients. There were also variations in management of concurrent psychiatric symptoms and dementia. Notably, over 50% of participants reported improvements in PD recognition and management by following the guidelines.

Conclusions: The increasing use of Chinese clinical practice guidelines for PD management is having a positive impact on the optimization of care, which in turn offers important economic benefits.

Keywords: Parkinson’s disease, Surveys and questionnaires, Guideline, Disease management

Background

Being one of the most common neurodegenerative disease worldwide, Parkinson’s disease (PD), with its high prevalence and incidence among aged people, carries a huge economic burden in China and presents with some unique features in Chinese population [1]. To address the aging crisis, the Chinese Parkinson’s Disease & Movement Disorders Society (CMDS), Neurology Branch of Chinese Medical Association has consecutively issued three versions of management guidelines for PD since 2006 [2–4]. Drawing upon four eminent guidelines globally ahead, which were formulated respectively by the Movement Disorder Society (MDS) [5], the American Academy of Neurology (AAN) [6–9], the European Federation of Neurological Societies (EFNS) [10], and the UK’s National Institute for Health and Care Excellence (NICE) [11] — the CMDS guidelines aim to guide the general direction of PD treatment in order to improve the current management standards in China. A key unique individualized treatment recommendation was the principles of dosage titration and a satisfactory clinical effect with a low dose, i.e., “low and slow”, should be followed to avoid acute adverse reactions and to reduce the incidence of long-term motor complications, as important therapeutic strategies in optimizing and standardizing treatment. Specifically, we recommend the principles of medication should be aiming at an optimal status for working and living quality, rather than full-dosage administration [12].

Aiming to acquire the real situation of PD treatment in China, in 2011 we conducted a pilot survey and the results showed significant differences in treatment options and an obvious variation before and after referring to PD guidelines among GPs, general neurologists and
movement disorders specialists [13]. Given the relatively small sample size of enrolled doctors involved previously, we launched a national survey at a larger scale and specify our research on the latest edition of the PD guideline, hoping to update our awareness of current PD management in China and measure the impact of the latest version (2014). Thus, this survey would evaluate the status quo and shed new light on the future control and management of PD.

Methods

Recruitment

This cross-sectional survey on doctors was performed between December 2015 and February 2016. One hundred and thirty-eight hospitals of different levels were chosen randomly from 30 cities across China. We enrolled 717 doctors in the survey and classified them into three categories: (1) GPs—most belong to general physicians; (2) General neurologists—who specialize in general neurology other than movement disorders; (3) Movement disorders specialists—neurologists with a specific focus on movement disorders, who regularly attend the movement disorders clinics. Among the chosen hospitals, 96% were ranked as tertiary hospitals according to the current grading measures issued by the PRC National Health and Family Planning Commission, which classes hospitals as tertiary if they are characterized by comprehensive multiple functions with specialization in all-purpose high-quality medical services and academic researches across different areas.

Research content

We asked enrolled doctors to complete a 96-item questionnaire covering all aspects of PD, including relevant methods on PD management, and the various therapeutic options they offered to patients. The questionnaire was designed by two of the authors (Dr. Gang Wang and Dr. Sheng-Di Chen) with approval from the Research Ethics Committee, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. The study included three stages, as following:

Stage 1: Background Acquisition: We gathered demographic information from the participants enrolled in the study in order to examine the distribution of the samples. We also assessed the level of understanding on a general basis in order to obtain an overall standard of recognition with regard to PD among the participants.

Stage 2: Differences in PD therapy according to varied clinicians, levels of hospital and city: We questioned participants with detailed and targeted questions on the different medications they tended to offer PD patients who presented with various symptoms. In order to evaluate the whole situation on a more comparable and meticulous basis, we classified the participants into three categories: by clinicians (GPs/Neurologist/Specialist), level of hospital, and hierarchy of city they worked in (as defined by the general economic status of the city).

Stage 3: Guideline’s impact on PD recognition and treatment: Finally, we attempted to investigate the disparity in the understanding and therapeutic methods of PD via the intervention of the latest version CMDS Guidelines (2014) and observed the changes in doctors on how they viewed and dealt with PD after adopting the guideline. The comparison of the two phrases (before and after the release of the guidelines) would be beneficial for the future training of the physicians in the management of PD.

Statistical analysis

All statistics were evaluated and addressed by members of an independent third party, with no underlying competing interests involved. Categorical variables were displayed by frequencies and percentages. The raw data analysis was based on contingency tables. All statistical analyses were performed using SAS version 9.4 software. Chi-square test was used for statistical analysis, and a $P$-value $< 0.05$ was considered significant.

Results

Demographics

A total of 717 (Male: female = 43%; 57%) participants were enrolled and mostly aged between 35 and 60 years (66%). Six hundred eighty-four participants (96.2%) were doctors of tertiary hospitals. As for the clinician types, 54% of them were general neurologists, with 28% of specialists in PD, others (18%) were GPs. Among all, 70.4% had no academic memberships, while 17.9% were members of CMDS in China. We also investigated the general level of CME of PD among physicians from various departments. Notably, there were significant differences ($p < 0.05$) in their familiarity with PD guidelines, exchange of academic experience, and level of research for PD.

Differences in PD therapy according to various clinicians, hospitals and cities

With each of the three categories, we sought participants’ opinions on the same set of therapeutic measures. Across various clinicians, there was a lack of consensus on several treatment issues, such as the first choice of medication for patients without cognitive decline, management on wearing off phenomenon, peak-dose dyskinesia and morning dystonia (see Table 1). They also thought differently on the management of PD with dementia and/or psychiatric symptoms. When faced with
psychiatric symptoms in advanced stage patients, most of the PD specialties (62.0%) would reduce or stop the anti-PD medication, while only 33.0% of GPs would copy the same strategy ($\chi^2(N = 711) = 26.4027$, $p < 0.0001$). However, regardless of their clinician types, most of the participants agreed on the usage of MAO-B inhibitors, which they prescribed for 25–50% of their PD patients to alleviate their symptoms. Nevertheless, there was disagreement about which type of PD might benefit more from MAO-B inhibitors, and an extremely significant disparity ($p < 0.0001$) on familiarity with the use of disease-modifying/neuroprotective therapy ($\chi^2(N = 711) = 42.9005$, $p < 0.0001$), Rivastigmine for PDD patients ($\chi^2(N = 711) = 20.2759$, $p < 0.0001$), and antipsychotics for psychiatric symptoms management ($\chi^2(N = 711) = 21.8987$, $p < 0.0001$).

With regard to different class of hospital, we found that all participating hospitals were in agreement on most of the questions, including the treatment of PD patients aged < 65 years without cognitive decline, management of wearing off phenomenon, peak-dose dyskinesia, and morning dystonia. They also shared similar opinions on treatment strategies for mental disorder and psychiatric symptoms. Some of them had slight differences in treating constipation and held opposite views on continuous dopaminergic stimulation (CDS). But there were no significant differences in the usage of MAO-B inhibitors and the management of Restless legs syndrome (RLS).

Regarding to financial status of the cities in which the participants were working, we discovered that most of the questions we devised received similar responses—that is, no significant differences in PD treatment and understanding were found among the cities we investigated.

### Table 1: Preferred medication for PD patients under specific circumstances among doctors of different specialties

| Items                        | Total ($n = 711$) | General physicians ($n = 130$) | General neurologists ($n = 381$) | Movement disorders specialists ($n = 200$) | $\chi^2$ | $p$ value |
|------------------------------|------------------|-------------------------------|---------------------------------|------------------------------------------|--------|-----------|
| **Age < 65 years without cognitive impairment** |                  |                               |                                 |                                          |        |           |
| Levodopa                     | 185 (26.0%)      | 25 (19.2%)                    | 106 (27.8%)                     | 54 (27.0%)                               | 3.8551 | 0.1455    |
| Dopamine agonists            | 333 (46.8%)      | 38 (29.2%)                    | 177 (46.5%)                     | 118 (59.0%)                              | 28.0886| < 0.0001  |
| MAO-B inhibitors             | 164 (23.1%)      | 20 (15.4%)                    | 86 (22.6%)                      | 58 (29.0%)                               | 8.3434 | 0.0154    |
| Benzhexol                    | 49 (6.9%)        | 4 (3.1%)                      | 25 (6.6%)                       | 20 (10.0%)                               | 6.0243 | 0.0492    |
| Amantadine                   | 101 (14.2%)      | 13 (10.0%)                    | 55 (14.4%)                      | 33 (16.5%)                               | 2.7671 | 0.2507    |
| Levodopa + COMT inhibitors   | 95 (13.4%)       | 19 (14.6%)                    | 48 (12.6%)                      | 28 (14.0%)                               | 0.4386 | 0.8031    |
| **Age > 65 years without cognitive impairment** |                  |                               |                                 |                                          |        |           |
| Levodopa                     | 345 (48.5%)      | 42 (32.3%)                    | 187 (49.1%)                     | 116 (58.0%)                              | 20.9235| < 0.0001  |
| Dopamine agonists            | 180 (25.3%)      | 22 (16.9%)                    | 99 (26.0%)                      | 59 (29.5%)                               | 6.7851 | 0.0336    |
| MAO-B inhibitors             | 101 (14.2%)      | 15 (11.5%)                    | 62 (16.3%)                      | 24 (12.0%)                               | 2.8932 | 0.2354    |
| Benzhexol                    | 32 (4.5%)        | 5 (3.9%)                      | 19 (5.0%)                       | 8 (4.0%)                                 | 0.4558 | 0.7962    |
| Amantadine                   | 69 (9.7%)        | 8 (6.2%)                      | 44 (11.6%)                      | 17 (8.5%)                                | 3.6800 | 0.1588    |
| Levodopa + COMT inhibitors   | 145 (20.4%)      | 22 (16.9%)                    | 82 (21.5%)                      | 41 (20.5%)                               | 1.2648 | 0.5313    |
| **Wearing off phenomenon**   |                  |                               |                                 |                                          |        |           |
| Add levodopa dose            | 127 (17.9%)      | 15 (11.5%)                    | 67 (17.6%)                      | 45 (22.5%)                               | 6.4953 | 0.0389    |
| Adjust protein diet          | 181 (25.5%)      | 18 (13.9%)                    | 87 (22.8%)                      | 76 (38.0%)                               | 27.1973| < 0.0001  |
| Switch from standard levodopa to CR levodopa | 260 (36.6%) | 30 (23.1%)                    | 140 (36.8%)                     | 90 (45.0%)                               | 16.3361| 0.0003    |
| Add COMT inhibitors or MAO-B inhibitors | 326 (45.9%) | 48 (36.9%)                    | 163 (42.8%)                     | 115 (57.5%)                              | 16.5500| 0.0003    |
| Recommend surgical treatment | 83 (11.7%)       | 7 (5.4%)                      | 35 (9.2%)                       | 41 (20.5%)                               | 22.3837| < 0.0001  |
| **Peak-dose dyskinesia**     |                  |                               |                                 |                                          |        |           |
| Reduce levodopa dose, add its frequency | 296 (41.6%) | 7 (28.5%)                      | 156 (40.9%)                     | 103 (51.5%)                              | 17.3687| 0.0002    |
| Reduce levodopa dose, add dopamine agonists | 319 (44.9%) | 33 (25.4%)                    | 168 (44.1%)                     | 118 (59.0%)                              | 36.1891| < 0.0001  |
| Reduce levodopa dose, add COMT inhibitors | 249 (35.0%) | 33 (25.4%)                    | 129 (33.9%)                     | 87 (43.5%)                               | 11.8497| 0.0027    |
| Reduce levodopa dose, add MAO-B inhibitors | 204 (28.7%) | 23 (17.7%)                    | 101 (26.5%)                     | 80 (40.0%)                               | 21.0749| < 0.0001  |
| Add amantadine               | 182 (25.6%)      | 20 (15.4%)                    | 85 (22.3%)                      | 77 (38.5%)                               | 26.7639| < 0.0001  |
| Switch from CR levodopa to standard levodopa | 110 (15.5%) | 16 (12.3%)                    | 43 (11.3%)                      | 51 (25.5%)                               | 21.4792| < 0.0001  |

*Six participants supply insufficient data and not included in the present table.
Guideline's impact on PD recognition and treatment
Prominent changes have been found. 68.3% of participants agreed with a “low and slow” and dosage titration method as the PD medication principle. In addition to different clinical feature of each patient, 77.7% of participants stressed the necessity of taking ages into account. Specifically, for the treatment of patients aged > 65 years, the top three preferred therapies before the guidelines were levodopa (75.7%), dopamine agonists and MAO-B inhibitors; 29.1% would consider trying a combination of levodopa and catechol-O-methyl transferase (COMT) inhibitors, which have superseded MAO-B inhibitors as the third most common option after the guidelines issued. Patients with wearing off phenomenon were likely to receive more doses of levodopa (52.9%) before the guidelines were issued; now, they would be given COMT inhibitors and MAO-B inhibitors (66.9%) instead. Most participants agreed with a 200-300 mg per day as the recommended starting dose for levodopa treatment. Memantine has been acknowledged as one of the preferred options (57.9%) for treating Parkinson's disease with dementia (PDD) ($\chi^2 (N = 717) = 21.1521, \ p < 0.0001$) (see Table 2).

We tallied the general satisfaction on the updated guidelines at the end of our investigation. More than 95% of the respondents confirmed its efficiency and application value. Importantly, 36.1% of participants reported a 25–50% of improvement in PD recognition, and 73.5% of them responded ≥25% increased accuracy in diagnosis. These findings reflect the benefit of the wider use of the guidelines.

Discussion
The purpose of this investigation is to determine at what level our neurologists are on the PD recognition and therapeutic methods. The current situation in China concerning PD management is that this disease is not only treated in neurological department, but non-neurology as well. What's more, the attending doctors are not simply limited to PD professions, but general neurologist of no PD-treating experience, or even physicians of other departments also. We deem it necessary to gain a thorough and validated situation of status quo on how the PD treatment is really carried out in China and the differences in therapeutic level among doctors of distinguished backgrounds. Supposing that the results of this survey shows significant differences in PD recognition and treatment methods, it is hopefully an optimal guidance for further reformation and improvement in this particular field.

During stage 1, we gathered information of participants involved in this study and classified their backgrounds. Female doctors made up of 57% of the total, and 66% of the samples were in the age group of 35–60 years. With 78% of them selected in first-tier or quasi first-tier cities and 98% worked in tertiary class hospitals, we could determine that this study is highly representative in large public hospitals among capital cities with integrated financial and economic centers in China. During stage 2, we asked the participants to fill in the questionnaire which contains clinical tendency on PD and their personal understanding on certain therapy. We found that the most notable discrepancies came from the feedbacks given by doctors of different specialties. Among which, highly significant differences were seen not only in guideline reference, academic exchanging, researching experience, but were not rare in detailed diagnostic methods like Madopar loading test on suspected patients and MRI application. Situations like these further substantiate our hypothesis that PD treatment in China have not been completely standardized so far. When compared on the ground of distinguished levels of hospitals and cities, we discovered minor differences, indicating the fact that the diagnostic and therapeutic level among hospitals and cities are generally similar, with no significant differences exposed. During stage 3, we discovered an inspirational phenomenon that the treating methods and PD recognition have prominently ameliorated after referring to the CMDS guidelines. Moreover, symptoms presented on PD patients have been significantly improved as well, as over half of the doctors surveyed reported improvements in their patients. Specifically, 36.8% of the participants confirmed an over 50% of improvements during clinical practice; while 62.1 and 63.1% of participants affirmed a reduction in patients with wearing off phenomenon and peak-dose dyskinesia, respectively. In short, the guideline is markedly beneficial to reasonable PD medications strategy, and hopefully, its dissemination will greatly enhance the standard of our PD management.

Compared to the guidelines issued before represented by MDS, etc., CMDS guidelines has a relatively short history. When first issued in 2006, it has been updated regularly and remained one of the young members among the family of PD guidelines worldwide. Its localization strategy in optimizing and standardizing management of PD, especially its emphasis about “low and slow”, have covered a large range of patients in need, and is conducive to disease management in a prolonged period [5, 6]. Inspirationally, we found that the clinical guideline is already helping the standardization of practice via improving the level of clinicians. It not only improved the diagnostic accuracy, but decreased the motor complications as well, which is in consistent with another study we have done recently [6].

However, since the survey was performed on doctors from tertiary class hospitals only, with no data gathered from the patients, we have not drawn any objective statistics that could directly show the improvement of the
### Table 2: The impact of PD guidelines reference on the selection of medication under specific circumstances

| Items                                                                 | Overall (n = 717) | Haven’t read the PD guidelines (n = 57) | Have read the PD guidelines (n = 660) | $\chi^2$  | P value |
|-----------------------------------------------------------------------|-------------------|----------------------------------------|--------------------------------------|-----------|---------|
| **Age < 65 years without cognitive impairment**                        |                   |                                        |                                      |           |         |
| Levodopa                                                              | 185 (25.8%)       | 5 (8.8%)                               | 180 (27.3%)                          | 9.3807    | 0.0022  |
| Dopamine agonists                                                     | 334 (46.6%)       | 4 (7.0%)                               | 330 (50.0%)                          | 38.9561   | <0.0001 |
| MAO-B inhibitors                                                      | 164 (22.9%)       | 2 (3.5%)                               | 162 (24.6%)                          | 13.1620   | 0.0003  |
| Benzhexol                                                             | 49 (6.8%)         | 0 (0.0%)                               | 49 (7.4%)                            | 4.5422    | 0.0331  |
| Amantadine                                                            | 101 (14.1%)       | 1 (1.8%)                               | 100 (15.2%)                          | 7.7814    | 0.0053  |
| Levodopa + COMT inhibitors                                            | 95 (13.3%)        | 1 (1.8%)                               | 94 (14.2%)                           | 7.1189    | 0.0076  |
| **Age > 65 years without cognitive impairment**                       |                   |                                        |                                      |           |         |
| Levodopa                                                              | 345 (48.1%)       | 7 (12.3%)                               | 338 (51.2%)                          | 31.8549   | <0.0001 |
| Dopamine agonists                                                     | 181 (25.2%)       | 3 (5.3%)                               | 178 (27.0%)                          | 13.1001   | 0.0003  |
| MAO-B inhibitors                                                      | 101 (14.1%)       | 3 (5.3%)                               | 98 (14.9%)                           | 3.9834    | 0.0460  |
| Benzhexol                                                             | 32 (4.5%)         | 0 (0.0%)                               | 32 (4.9%)                            | 2.8927    | 0.0890  |
| Amantadine                                                            | 69 (9.6%)         | 2 (3.5%)                               | 67 (10.2%)                           | 2.6620    | 0.1028  |
| Levodopa + COMT inhibitors                                            | 145 (20.2%)       | 1 (1.8%)                               | 144 (21.8%)                          | 13.0918   | 0.0003  |
| **Wearing off phenomenon**                                            |                   |                                        |                                      |           |         |
| Add levodopa dose                                                     | 127 (17.7%)       | 3 (5.3%)                               | 124 (18.8%)                          | 6.5847    | 0.0103  |
| Adjust protein diet                                                   | 182 (25.4%)       | 2 (3.5%)                               | 180 (27.3%)                          | 15.6441   | <0.0001 |
| Switch from standard levodopa to CR levodopa                        | 261 (36.4%)       | 3 (5.3%)                               | 258 (39.1%)                          | 25.9346   | <0.0001 |
| Add COMT inhibitors or MAO-B inhibitors                               | 327 (45.6%)       | 5 (8.8%)                               | 322 (48.3%)                          | 33.8682   | <0.0001 |
| Recommend surgical treatment                                          | 83 (11.6%)        | 0 (0.0%)                               | 83 (12.6%)                           | 8.1066    | 0.0044  |
| **Peak-dose dyskinesia**                                              |                   |                                        |                                      |           |         |
| Reduce levodopa dose, add its frequency                               | 297 (41.4%)       | 5 (8.8%)                               | 292 (44.2%)                          | 27.2061   | <0.0001 |
| Reduce levodopa dose, add dopamine agonists                           | 319 (44.5%)       | 7 (12.3%)                               | 312 (47.3%)                          | 26.0137   | <0.0001 |
| Reduce levodopa dose, add COMT inhibitors                             | 251 (35.0%)       | 5 (8.8%)                               | 246 (37.3%)                          | 18.7324   | <0.0001 |
| Reduce levodopa dose, add MAO-B inhibitors                            | 206 (28.7%)       | 4 (7.0%)                               | 202 (30.6%)                          | 14.2578   | 0.0002  |
| Add amantadine                                                        | 182 (25.4%)       | 2 (3.5%)                               | 180 (27.3%)                          | 15.6441   | <0.0001 |
| Switch from CR levodopa to standard levodopa                         | 110 (15.3%)       | 0 (0.0%)                               | 110 (16.7%)                          | 11.2216   | 0.0008  |
| **PD with psychosis (advanced stage)**                                |                   |                                        |                                      |           |         |
| Reduce levodopa dose                                                  | 147 (20.5%)       | 2 (3.5%)                               | 145 (22.0%)                          | 10.9712   | 0.0009  |
| Add antipsychotics                                                   | 321 (44.8%)       | 11 (19.3%)                              | 310 (47.0%)                          | 16.2481   | <0.0001 |
| **PD with visual hallucination and delirium during treatment**       |                   |                                        |                                      |           |         |
| Clozapine                                                            | 267 (37.2%)       | 13 (22.8%)                              | 254 (38.5%)                          | 5.5181    | 0.0188  |
| Olanzapine                                                           | 301 (42.0%)       | 22 (38.6%)                              | 279 (42.3%)                          | 0.2911    | 0.5895  |
| Quetiapine                                                           | 301 (42.0%)       | 9 (15.8%)                              | 292 (44.2%)                          | 17.4394   | <0.0001 |
| Risperidone                                                          | 85 (11.9%)        | 3 (5.3%)                               | 82 (12.4%)                           | 2.5749    | 0.1086  |
| **PD with depression**                                               |                   |                                        |                                      |           |         |
| Tricyclic antidepressants                                            | 59 (8.2%)         | 8 (14.0%)                              | 51 (7.7%)                            | 2.7645    | 0.0964  |
| SSRIs, e.g. sertraline                                               | 487 (67.9%)       | 39 (68.4%)                              | 448 (67.9%)                          | 0.0071    | 0.9329  |
| Pramipexole                                                          | 420 (58.6%)       | 20 (35.1%)                              | 400 (60.6%)                          | 14.0811   | 0.0002  |
| **PD with dementia (PDD)**                                           |                   |                                        |                                      |           |         |
| Huperzine A                                                          | 82 (11.4%)        | 1 (1.8%)                                | 81 (12.3%)                           | 5.7312    | 0.0167  |
| Donepezil                                                           | 346 (48.3%)       | 13 (22.8%)                              | 333 (50.5%)                          | 16.0620   | <0.0001 |
| Rivastigmine tartrate                                                | 275 (38.4%)       | 7 (12.3%)                              | 268 (40.6%)                          | 17.8047   | <0.0001 |
effectiveness of PD management and the health condition on patients’ perspective. Further researches need to be conducted in order to make up for this deficiency.

Conclusions
In general, the CMDS guidelines has demonstrated a clear impact on therapeutic strategies for PD, and the clinical management of PD in China could be improved considerably if the deficiencies revealed in this study could be effectively addressed. Hopefully, the wider dissemination of the CMDS guidelines will greatly enhance the standard of China’s PD management continuously in the long run.

Abbreviations
AAN: American Academy of Neurology; CDS: Continuous dopaminergic stimulation; CMDS: Chinese Parkinson’s Disease & Movement Disorders Society; EFNS: European Federation of Neurological Societies; GPs: General practitioners; MAO-B: Monoamine oxidase BCOMT: catechol-O-methyl transferase; MDS: Movement Disorder Society; NICE: UK’s National Institute for Health and Care Excellence; PD: Parkinson’s disease; PDD: Parkinson’s disease with dementia; RLS: Restless legs syndrome

Funding
This work was supported by the National Natural Science Foundation of China [grant numbers 91332107] and the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [grant numbers 20172001]. Lundbeck China provided the fund for medical editing; and PAR-EXEL gave the assistance on medical editor.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
GW and HLC contributed to the drafting of the manuscript; GW and SDC designed the study, analyzed the data and revised the manuscript; others participated in the data collecting and study design. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study is approved by the Ethics Committee of Ruijin Hospital, affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China and all participants gave written informed consent for participation and to publication.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 5 September 2017 Accepted: 7 August 2018
Published online: 22 August 2018

Table 2 The impact of PD guidelines reference on the selection of medication under specific circumstances (Continued)

| Items                                                                 | Overall (n = 717) | Haven’t read the PD guidelines (n = 57) | Have read the PD guidelines (n = 660) | χ²       | P value  |
|----------------------------------------------------------------------|-------------------|----------------------------------------|--------------------------------------|----------|----------|
| Memantine                                                           | 397 (55.4%)       | 15 (26.3%)                             | 382 (57.9%)                          | 21.1521  | < 0.0001 |
| Traditional Chinese Medicine (TCM), e.g. ginkgo leaf               | 82 (11.4%)        | 1 (1.8%)                               | 81 (12.3%)                           | 5.7312   | 0.0167   |
| PD with periodical limb movement syndrome (PLMS) or restless legs syndrome (RLS) |                   |                                        |                                      |          |          |
| Levodopa                                                           | 153 (21.3%)       | 6 (10.5%)                              | 147 (22.3%)                          | 4.3130   | 0.0378   |
| Dopamine agonists                                                  | 376 (52.4%)       | 6 (10.5%)                              | 370 (56.1%)                          | 43.6187  | < 0.0001 |
| Amantadine                                                         | 17 (2.4%)         | 0 (0.0%)                               | 17 (2.6%)                            | 1.5038   | 0.2201   |
| Benzodiazipines                                                    | 94 (13.1%)        | 3 (5.3%)                               | 91 (13.8%)                           | 3.3472   | 0.0673   |

References
1. Wang G, Cheng Q, Zheng R, Tan Y, Sun Y, Zhou H, Ye X, Wang Y, Wang Z, Sun B, et al. Economic burden of Parkinson’s disease in a developing country: a retrospective cost analysis in Shanghai, China. Mov Disord. 2006;21(9):1439–43.
2. Chen SD. The guideline for management of Parkinson’s disease in China. Chin J Neurol. 2006;39:409–12.
3. Chen SD. The guideline for management of Parkinson’s disease in China (second edition). Chin J Neurol. 2009;42(5):352–5.
4. Chen SD. The guideline for management of Parkinson’s disease in China (third edition). Chin J Neurol. 2014;47(6):428–33.
5. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.
6. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman LM, Gronseth G, Weiner WJ. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the quality standards Subcommittee of the American Academy of neurology. Neurology. 2006;66(7):996–1002.
7. Pahwa R, Factor SA, Lyons KE, Ordone WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the quality standards Subcommittee of the American Academy of neurology. Neurology. 2006;66(7):983–95.
8. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the quality standards Subcommittee of the American Academy of neurology. Neurology. 2006;66(7):976–82.
9. Montgomery EB Jr. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the quality standards Subcommittee of the American Academy of neurology. Neurology. 2007;68(2):164. author reply 164.
10. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, et al. EFNS/EMS-EFNS [corrected] recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol. 2013;20(1):16–34.
11. Ryton BA, Liddle BJ. Implementing NICE clinical guidelines on Parkinson’s disease. Clin Med(Lond). 2009;9(5):436–40.
12. Chen S, Chin P, Sun S, Chen H, Zhang B, Le W, Liu C, Peng G, Tang B, Wang L, et al. The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease. Transl Neurodegener. 2016;5:12.
13. Chen W, Chen S, Xiao Q, Wang G, Chen SD. Current clinical practice for Parkinson’s disease among Chinese physicans, general neurologists and movement disorders specialists: a national survey. BMC Neurol. 2012;12:155.